Workshop
CLIN
1. Extrapulmonary Benefits and Pharmacogenomics in Lung Transplant Recipients With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy – Presented by Asma Algarawi
2. Risk of Cancer in Patients With Cystic Fibrosis Following Lung Transplantation – Presented by Joshua Ostrenga
3. Improving Rate of Multi-Disciplinary CF Visits for People With CF Post-Lung Transplantation Through Quality Improvement Methodology – Presented by Lauren Mitchell
4. Characterizing Patterns in Lung Transplantation Referral for People With Advanced Cystic Fibrosis Lung Disease – Presented by William Brandon
5. Results of the LTx READY CF 2 Multicenter Trial of Take on Transplant, a CF-Specific Lung Transplant Education Resource – Presented by Tijana Milinic
Kathleen Ramos
University of Washington School of Medicine
Sarah Kiel, MD
Div. of Pulmonary and Critical Care Medicine, University of Minnesota
Asma Algarawi, MBBS
Harvard Medical school
Josh S. Ostrenga, MS
Cystic Fibrosis Foundation
Lauren Mitchell, PT, DPT
Johns Hopkins Hospital
William M. Brandon
University of Washington School of Medicine
Tijana Milinic
University of Washington School of Medicine